Drugs / Fluarix Quadrivalent
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT01702454 | Oct 2012 → May 2013 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03686514 | Oct 2018 → Jun 2020 | influenza | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT03701061 | Oct 2018 → Feb 2019 | avian influenza | Emory University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03275389 Comparator | Sep 2017 → Mar 2020 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05827978 Comparator | Apr 2023 → Jun 2024 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05566639 Comparator | Sep 2022 → Jan 2024 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03739112 Comparator | Sep 2018 → May 2019 | respiratory tract infectious disorder, viral infectious disease | Medicago | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluarix Quadrivalent | “A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study” NCT03701061 ↗6“Fluarix Quadrivalent” NCT05827978 ↗ |
| Known as | GSK2321138A | “Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Quadrivalent Seasonal Influenza Candidate Vaccine GSK2321138A, Administered to Children Who Previously...” NCT01702454 ↗ |
| Modality | Vaccine | “GSK Biologicals' Quadrivalent Seasonal Influenza Candidate Vaccine GSK2321138A” NCT01702454 ↗ |
| Route | Intramuscular | “The vaccine was administered intramuscularly in the deltoid region of arm.” NCT01702454 ↗ |